Profile data is unavailable for this security.
About the company
Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
- Revenue in GBP (TTM)72.77m
- Net income in GBP-13.78m
- Incorporated2004
- Employees601.00
- LocationAllergy Therapeutics PLCDominion WayWORTHING BN14 8SAUnited KingdomGBR
- Phone+44 190 384 4700
- Fax+44 190 384 4726
- Websitehttps://www.allergytherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hellenic Dynamics PLC | -100.00bn | -100.00bn | 21.61m | 25.00 | -- | 1.61 | -- | -- | -- | -- | -- | 0.0011 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Science in Sport PLC | 65.55m | -12.54m | 25.86m | 218.00 | -- | 0.5553 | -- | 0.3945 | -0.0913 | -0.0913 | 0.4782 | 0.2701 | 0.9498 | 4.01 | 4.95 | 300,706.40 | -18.17 | -9.41 | -24.12 | -11.30 | 45.67 | 49.61 | -19.13 | -11.80 | 0.6709 | -29.53 | 0.2825 | -- | 24.21 | 38.56 | -294.50 | -- | 46.77 | -- |
| Skinbiotherapeutics PLC | 129.80k | -3.00m | 26.84m | 12.00 | -- | 20.04 | -- | 206.75 | -0.0192 | -0.0192 | 0.0008 | 0.0077 | 0.0393 | 0.1843 | 0.3611 | 10,816.67 | -90.97 | -38.99 | -108.04 | -41.85 | 64.48 | -- | -2,313.31 | -10,323.93 | 1.64 | -330.70 | 0.0828 | -- | -- | -- | -94.88 | -- | 4.10 | -- |
| Destiny Pharma PLC | 0.00 | -6.50m | 28.39m | 20.00 | -- | 2.87 | -- | -- | -0.0928 | -0.0928 | 0.00 | 0.104 | 0.00 | -- | -- | 0.00 | -76.16 | -47.98 | -85.94 | -52.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.80 | -- | -45.97 | -- |
| Chill Brands Group PLC | -430.07k | -5.29m | 32.36m | 5.00 | -- | 28.73 | -- | -- | -0.0235 | -0.0237 | -0.0019 | 0.0039 | -0.0809 | 0.0349 | -- | -86,014.00 | -99.49 | -59.54 | -120.93 | -81.31 | -- | -- | -- | -455.17 | 5.21 | -- | 0.7817 | -- | 94.52 | -- | -16.08 | -- | -31.94 | -- |
| Tissue Regenix Group PLC | 19.66m | -2.17m | 36.10m | 79.00 | -- | 1.44 | -- | 1.84 | -0.0308 | -0.0308 | 0.2795 | 0.3568 | 0.5306 | 1.28 | 5.50 | 248,893.00 | -5.63 | -16.79 | -6.25 | -18.41 | 46.00 | 46.19 | -10.61 | -43.22 | 1.68 | -2.46 | 0.2402 | -- | 23.95 | 29.43 | 43.76 | -- | 30.58 | -- |
| Poolbeg Pharma PLC | 0.00 | -4.69m | 40.50m | 12.00 | -- | 2.21 | -- | -- | -0.0094 | -0.0094 | 0.00 | 0.0367 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.60 | -- | -- | -- |
| C4X Discovery Holdings PLC | 4.31m | -7.52m | 41.16m | 48.00 | -- | 3.04 | -- | 9.55 | -0.0314 | -0.0314 | 0.018 | 0.0538 | 0.2643 | -- | 7.57 | 89,770.84 | -46.14 | -52.11 | -51.65 | -59.35 | 97.84 | 98.57 | -174.56 | -206.69 | -- | -5,085.00 | 0.0415 | -- | -52.16 | 79.96 | -112.28 | -- | -16.47 | -- |
| Allergy Therapeutics plc | 72.77m | -13.78m | 42.44m | 601.00 | -- | 1.06 | -- | 0.5833 | -0.022 | -0.022 | 0.1094 | 0.0587 | 0.9002 | 2.09 | 8.72 | -- | -17.04 | -2.20 | -21.93 | -2.87 | 68.03 | 73.25 | -18.93 | -2.09 | 1.74 | -29.72 | 0.2152 | -- | -13.71 | 2.56 | -577.34 | -- | 13.67 | -- |
| Venture Life Group PLC | 43.98m | 520.00k | 47.12m | 153.00 | 106.43 | 0.6228 | 7.98 | 1.07 | 0.0035 | 0.0035 | 0.3297 | 0.5981 | 0.3842 | 2.50 | 3.07 | 287,451.00 | 0.4543 | 1.75 | 0.5151 | 2.01 | 40.17 | 40.30 | 1.18 | 4.41 | 1.34 | 2.19 | 0.2619 | 0.00 | 34.24 | 22.33 | -78.35 | -- | 37.59 | -- |
| Shield Therapeutics PLC | 4.47m | -40.44m | 48.13m | 23.00 | -- | 3.77 | -- | 10.77 | -0.1661 | -0.1661 | 0.0188 | 0.0179 | 0.1344 | 1.60 | 1.08 | -- | -121.66 | -38.57 | -154.17 | -43.09 | 44.71 | 80.67 | -905.40 | -253.15 | 0.8118 | -- | 0.5291 | -- | 194.08 | 47.63 | -105.53 | -- | -11.08 | -- |
| CRUSHMETRIC Group Ltd | 910.93k | -195.99k | 48.23m | 6.00 | -- | -- | -- | 52.95 | -0.0022 | -0.0022 | 0.0104 | -0.0474 | 1.06 | 5.14 | 5.24 | -- | -64.23 | -118.75 | -- | -- | 46.12 | 38.24 | -60.68 | -156.87 | 0.0909 | -10.54 | -- | -- | -75.86 | -14.62 | -156.85 | -- | -- | -- |
| Spectral MD Holdings Ltd | 20.38m | -2.34m | 61.67m | 71.00 | -- | 6.36 | -- | 3.03 | -0.0173 | -0.0173 | 0.1505 | 0.0712 | 1.36 | -- | 13.61 | 287,030.00 | -15.63 | -- | -22.32 | -- | 42.72 | -- | -11.48 | -- | -- | -12.73 | 0.0788 | -- | 66.47 | -- | 44.50 | -- | -- | -- |
Data as of Dec 30 2022. Currency figures normalised to Allergy Therapeutics PLC's reporting currency: UK Pound GBX
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan Chase Bank, NA (Investment Management)as of 02 Mar 2023 | 124.00m | 0.00% |
| River & Mercantile Asset Management LLPas of 10 Apr 2023 | 28.70m | 0.00% |
| Odey Asset Management LLPas of 02 Mar 2023 | 9.16m | 0.00% |
| Medical Strategy GmbHas of 31 Jan 2023 | 3.64m | 0.00% |
| Hargreaves Lansdown Asset Management Ltd.as of 02 Mar 2023 | 3.54m | 0.00% |
| Santander Asset Management SA SGIICas of 02 Mar 2023 | 3.13m | 0.00% |
| Hauck Aufh�user Lampe Privatbank AGas of 02 Mar 2023 | 3.07m | 0.00% |
| West Yorkshire Pension Fundas of 02 Mar 2023 | 1.98m | 0.00% |
| Maitland Asset Management (Pty) Ltd.as of 02 Mar 2023 | 1.90m | 0.00% |
| Ninety One UK Ltd.as of 31 Aug 2022 | 1.90m | 0.00% |
More ▼
Data from 30 Sep 2021 - 31 Mar 2023Source: FactSet Research Systems Inc.
